The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 18, 2017.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 18.
Number 5: Dr Stanley Cohen, medical director of the Metroplex Clinical Research Center and clinical professor of internal medicine at the University of Texas Southwestern Medical School, says that patients should feel comfortable about using biosimilars to treat rheumatic diseases.
Number 4: A recent paper concludes that low-level anti-tumor necrosis factor anti-drug antibodies in patients with inflammatory bowel disease may be overcome by dose escalation or the addition of an immunomodulator.
Number 3: An international, multidisciplinary task force has released 8 consensus recommendations for the use of biosimilars to treat rheumatic diseases.
Number 2: On Wednesday, Pfizer filed suit against Johnson and Johnson in a Pennsylvania district court. Pfizer’s complaint alleges that the Remicade sponsor has been using anti-competitive means to block sales of its biosimilar infliximab, Inflectra.
Number 1: Dr Angus Worthing, practicing rheumatologist and vice chair of the Alliance for Transparent and Affordable Prescriptions, says that rebates for reference biologics reduce competition and lead to higher drug prices for patients.
Finally, last week, our newsletter asked for your input on the size of the cost-saving potential that biosimilar filgrastim provides to health plans. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.